JP Nadda says Govt vigilant about quality of medicines

Published On 2024-07-27 10:56 GMT   |   Update On 2024-07-27 10:56 GMT

New Delhi: The Indian government reassured that it has a robust system in place for examining medicines and has taken necessary actions regarding recent concerns about the quality of certain cough syrups exported to Africa. Minister of Chemicals and Fertilizers J.P. Nadda provided these assurances while addressing the Lok Sabha.

Nadda's remarks followed a query from Congress member Gaurav Gogoi, who had raised concerns over some cough syrups exported to Africa. The Minister emphasized that the government is closely monitoring the quality of medicines and is committed to preventing any future issues.

Advertisement
There is a robust system of examination of medicines in place, the minister said during the Question Hour and emphasised that the world's most effective and cheapest medicines are produced in India

Speaker Om Birla said there is a demand for medicines from India in all the countries he had been to as he has asked the government to increase exports of the medicines globally.

To a query on whether the government has taken note of certain comments of the Department of Pharmaceuticals against the reputation of small drugmakers, Nadda said a complaint was received against an Assistant Section Officer for sending an email to pharma associations using language that is not officially proper.
Advertisement
"Even though the communication was informal, a show-cause notice was issued to the concerned officer. The officer has apologised for the same. Nevertheless, competent authority has rejected the reply and initiated departmental proceedings against the erring officer," the minister said.
The Revamped Pharmaceuticals Technology Upgradation Scheme (PTUAS) is aimed at helping the pharmaceutical industry align its production process with best global standards, he said adding more than 100 applications have been received since the application window was opened from April 11, 2024.
"Seven applications have been approved and all the seven are MSMEs," he said.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News